Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma

Waiting for the Revolution

Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Salvatore Pisconti, Nicola Battelli, Francesco Massari

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Management of metastatic renal cell carcinoma has drastically changed in the last few years, witnessing the advent of more and more target therapies and, recently, of immune-checkpoint inhibitors. On the other hand, the adjuvant setting still lacks a clear beneficial treatment. Medical treatment still remains a compelling challenge. A large number of clinical trials is ongoing with the aim to identify new therapeutic approaches to expand the options in our repertoire. Several strategies are under investigation in renal cell carcinoma (RCC). These include new targeted agents and combinations of target therapy and immunotherapy. Programmed death receptor-1 (PD-1), programmed death receptor ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are just part of the intricate network that regulates our immune response to cancer cells. Co-stimulators, such as glucocorticoid-induced TNFR-related protein (GITR) and tumor necrosis factor receptor superfamily, member 4 (OX40), and co-repressors, example.g. T cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3), also take part. As knowledge of the functioning of the immune system grows, so do these pathways to target with new drugs. This review is an overview of the current state of the clinical research, providing a report of ongoing Phase I, II and III clinical trials for localized and metastatic RCC, including novel target therapies, novel immunotherapy agents and new combinations strategies.

Original languageEnglish (US)
JournalClinical Drug Investigation
DOIs
StatePublished - Jan 1 2019

Fingerprint

Renal Cell Carcinoma
Death Domain Receptors
Glucocorticoid-Induced TNFR-Related Protein
OX40 Receptor
Immunotherapy
Mucin-3
Therapeutics
CTLA-4 Antigen
Co-Repressor Proteins
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Lymphocyte Activation
Immune System
Clinical Trials
Ligands
T-Lymphocytes
Research
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma : Waiting for the Revolution. / Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Cimadamore, Alessia; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo; Pisconti, Salvatore; Battelli, Nicola; Massari, Francesco.

In: Clinical Drug Investigation, 01.01.2019.

Research output: Contribution to journalReview article

Mollica, V, Di Nunno, V, Gatto, L, Santoni, M, Cimadamore, A, Cheng, L, Lopez-Beltran, A, Montironi, R, Pisconti, S, Battelli, N & Massari, F 2019, 'Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution', Clinical Drug Investigation. https://doi.org/10.1007/s40261-019-00773-w
Mollica, Veronica ; Di Nunno, Vincenzo ; Gatto, Lidia ; Santoni, Matteo ; Cimadamore, Alessia ; Cheng, Liang ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Pisconti, Salvatore ; Battelli, Nicola ; Massari, Francesco. / Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma : Waiting for the Revolution. In: Clinical Drug Investigation. 2019.
@article{15f032ac0cb14c44840c728cc7275c4d,
title = "Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution",
abstract = "Management of metastatic renal cell carcinoma has drastically changed in the last few years, witnessing the advent of more and more target therapies and, recently, of immune-checkpoint inhibitors. On the other hand, the adjuvant setting still lacks a clear beneficial treatment. Medical treatment still remains a compelling challenge. A large number of clinical trials is ongoing with the aim to identify new therapeutic approaches to expand the options in our repertoire. Several strategies are under investigation in renal cell carcinoma (RCC). These include new targeted agents and combinations of target therapy and immunotherapy. Programmed death receptor-1 (PD-1), programmed death receptor ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are just part of the intricate network that regulates our immune response to cancer cells. Co-stimulators, such as glucocorticoid-induced TNFR-related protein (GITR) and tumor necrosis factor receptor superfamily, member 4 (OX40), and co-repressors, example.g. T cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3), also take part. As knowledge of the functioning of the immune system grows, so do these pathways to target with new drugs. This review is an overview of the current state of the clinical research, providing a report of ongoing Phase I, II and III clinical trials for localized and metastatic RCC, including novel target therapies, novel immunotherapy agents and new combinations strategies.",
author = "Veronica Mollica and {Di Nunno}, Vincenzo and Lidia Gatto and Matteo Santoni and Alessia Cimadamore and Liang Cheng and Antonio Lopez-Beltran and Rodolfo Montironi and Salvatore Pisconti and Nicola Battelli and Francesco Massari",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40261-019-00773-w",
language = "English (US)",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma

T2 - Waiting for the Revolution

AU - Mollica, Veronica

AU - Di Nunno, Vincenzo

AU - Gatto, Lidia

AU - Santoni, Matteo

AU - Cimadamore, Alessia

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Pisconti, Salvatore

AU - Battelli, Nicola

AU - Massari, Francesco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Management of metastatic renal cell carcinoma has drastically changed in the last few years, witnessing the advent of more and more target therapies and, recently, of immune-checkpoint inhibitors. On the other hand, the adjuvant setting still lacks a clear beneficial treatment. Medical treatment still remains a compelling challenge. A large number of clinical trials is ongoing with the aim to identify new therapeutic approaches to expand the options in our repertoire. Several strategies are under investigation in renal cell carcinoma (RCC). These include new targeted agents and combinations of target therapy and immunotherapy. Programmed death receptor-1 (PD-1), programmed death receptor ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are just part of the intricate network that regulates our immune response to cancer cells. Co-stimulators, such as glucocorticoid-induced TNFR-related protein (GITR) and tumor necrosis factor receptor superfamily, member 4 (OX40), and co-repressors, example.g. T cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3), also take part. As knowledge of the functioning of the immune system grows, so do these pathways to target with new drugs. This review is an overview of the current state of the clinical research, providing a report of ongoing Phase I, II and III clinical trials for localized and metastatic RCC, including novel target therapies, novel immunotherapy agents and new combinations strategies.

AB - Management of metastatic renal cell carcinoma has drastically changed in the last few years, witnessing the advent of more and more target therapies and, recently, of immune-checkpoint inhibitors. On the other hand, the adjuvant setting still lacks a clear beneficial treatment. Medical treatment still remains a compelling challenge. A large number of clinical trials is ongoing with the aim to identify new therapeutic approaches to expand the options in our repertoire. Several strategies are under investigation in renal cell carcinoma (RCC). These include new targeted agents and combinations of target therapy and immunotherapy. Programmed death receptor-1 (PD-1), programmed death receptor ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are just part of the intricate network that regulates our immune response to cancer cells. Co-stimulators, such as glucocorticoid-induced TNFR-related protein (GITR) and tumor necrosis factor receptor superfamily, member 4 (OX40), and co-repressors, example.g. T cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3), also take part. As knowledge of the functioning of the immune system grows, so do these pathways to target with new drugs. This review is an overview of the current state of the clinical research, providing a report of ongoing Phase I, II and III clinical trials for localized and metastatic RCC, including novel target therapies, novel immunotherapy agents and new combinations strategies.

UR - http://www.scopus.com/inward/record.url?scp=85064240107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064240107&partnerID=8YFLogxK

U2 - 10.1007/s40261-019-00773-w

DO - 10.1007/s40261-019-00773-w

M3 - Review article

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

ER -